Circumvention of cytarabine (Ara-C) resistance by 2-chloro-deoxyadenosine (2-CdA) in pediatric acute myeloid (AML) and acute lymphoblastic (ALL) leukemia: An in vitro study.

被引：0
|
作者：
Zwaan, CM
Kaspers, GJL
Pieters, R
Huismans, DR
Van Wering, ER
Janka-Schaub, GE
Creutzig, U
Henze, G
Veerman, AJP
机构：
[1] Vrije Univ Amsterdam, Univ Hosp Amsterdam, Dept Pediat Hematol Oncol, Amsterdam, Netherlands
[2] Sophia Childrens Hosp, Dept Hematol Oncol, Rotterdam, Netherlands
[3] Dutch Childhood Leukemia Study Grp, The Hague, Netherlands
[4] CoALL Study Grp, Hamburg, Germany
[5] AML BFM Study Grp, Munster, Germany
[6] BFM ALL Relapse Study Grp, Berlin, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1327
引用
收藏
页码：307A / 307A
页数：1
相关论文
共 50 条
  • [31] A microarray study of altered gene expression in Ara-C resistance in acute myeloid leukemia (Retraction of vol 21, pg 1093, 2007)
    Yin, B.
    Tsai, M. L.
    Hasz, D. E.
    Rathe, S. K.
    LeBeau, M.
    Largaespada, D. A.
    LEUKEMIA, 2010, 24 (08) : 1543 - 1543
  • [32] STUDY OF THE ROLE OF SPLICING FACTOR SRRM2 IN RESISTANCE TO CYTARABINE TREATMENT IN ACUTE MYELOID LEUKEMIA
    Morales, M. L.
    Garcia-Vicente, R.
    Alvarez, N.
    Rodriguez-Garcia, A.
    Ortiz-Ruiz, A.
    Reyes-Palomares, A.
    Ayala, R.
    Martinez-Lopez, J.
    Linares, M.
    HAEMATOLOGICA, 2020, 105 : 206 - 206
  • [33] Study of the Role of Splicing Factor SRRM2 in Cytarabine Treatment Resistance in Acute Myeloid Leukemia
    Morales, Maria Luz
    Garcia-Vicente, Roberto
    Sanchez-Redondo, Noemi Alvarez
    Garcia, Alba Rodriguez
    Ortiz-Ruiz, Alejandra
    Reyes-Palomares, Armando
    Hermouet, Sylvie
    Ayala, Rosa
    Martinez-Lopez, Joaquin
    Linares, Maria
    BLOOD, 2020, 136
  • [34] Randomized phase II study of clofarabine versus clofarabine plus low-dose cytarabine (ara-C) for patients (pts) ≥ 60 years (yrs) with newly diagnosed acute myeloid leukemia (AML).
    Faderl, S
    Ravandi-Kashani, F
    Ferrajoli, A
    Estrov, Z
    Wierda, W
    Verstovsek, S
    Garcia-Manero, G
    Estey, EE
    Kwari, M
    Kantarjian, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 591S - 591S
  • [35] Postremission therapy in adult acute myeloid leukemia (AML): A randomized comparison between high dose ara-C therapy and conventional consolidation therapy (JALSG AML 201 study).
    Miyawaki, Shuichi
    Ohtake, Shigeki
    Fujisawa, Shin
    Kiyoi, Hitoshi
    Shinagawa, Katsuji
    Usui, Noriko
    Miyamura, Koichi
    Nishimura, Miki
    Miyazaki, Yasushi
    Nishii, Kazuhiro
    Nagai, Tadashi
    Yamane, Takahisa
    Taniwaki, Masafumi
    Takahashi, Masatomo
    Yagasaki, Fumiharu
    Kimura, Yukihiko
    Asou, Norio
    Honda, Sumihisa
    Ohnishi, Kazunori
    Naoe, Tomoki
    Ohno, Ryuzo
    BLOOD, 2006, 108 (11) : 567A - 567A
  • [36] Phase I study of clofarabine plus Idarubicin and Clofarabine plus Idarubicin plus Cytarabine (ARA-C) in patients (PTS) with relapsed and primary refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML).
    Faderl, S
    Ferrajolil, A
    Wierda, W
    Verstovsek, S
    Ravandi-Kashani, F
    Garcia-Manero, G
    Estey, E
    Thomas, DA
    Kornblau, S
    Kwari, M
    Gandhi, V
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 501A - 501A
  • [37] A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia
    Wei Zhou
    Siying Li
    Hong Wang
    Jingfeng Zhou
    Shuyi Li
    Guofeng Chen
    Wei Guan
    Xianli Fu
    Clara Nervi
    Li Yu
    Yonghui Li
    Experimental Hematology & Oncology, 13
  • [38] A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia
    Zhou, Wei
    Li, Siying
    Wang, Hong
    Zhou, Jingfeng
    Li, Shuyi
    Chen, Guofeng
    Guan, Wei
    Fu, Xianli
    Nervi, Clara
    Yu, Li
    Li, Yonghui
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [39] A phase I trial of a single high dose of idarubicin combined with high dose cytarabine (ARA-C) as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia (ALL).
    Weiss, M
    Maslak, P
    Megherian, L
    Scheinberg, D
    BLOOD, 1995, 86 (10) : 3131 - 3131
  • [40] Phase II trial of 2-chlorodeoxyadenosine (2-CdA) in patients (PTS) with relapsed/refractory acute myeloid leukemia (AML). A study of the eastern cooperative oncology group (ECOG), e5995.
    Gordon, MS
    Young, ML
    Tallman, M
    Bennett, J
    Paietta, E
    Cripe, L
    Longo, W
    Gerad, H
    Banerjee, T
    Rowe, J
    BLOOD, 1997, 90 (10) : 3826 - 3826
12345